From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: is it time for a change of terminology?

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of liver disease in many parts of the world, causing considerable liver-related (steatohepatitis, cirrhosis, liver failure and hepatocellular carcinoma) and extra-hepatic morbidity and mortality (mainly cardiovascular disease, chronic kidney disease or certain types of extra-hepatic cancers). Recently, based on insights gained from the past two decades, an international panel of experts from 22 countries has taken the initiative to propose a new name and definition for NAFLD in adult individuals - that is, metabolic dysfunction-associated fatty liver disease. This proposed change in nomenclature is not simply a semantic revision, but may facilitate improved diagnosis of this common liver disease for health promotion, case identification, patient awareness, ongoing clinical trials and health services delivery. The aim of this commentary is to discuss the proposal for a change in nomenclature of this common and burdensome liver disease and to address the “pros and cons” for changing the name according to the perspective of different stakeholders.

Keywords

Nonalcoholic fatty liver disease / metabolic dysfunction-associated fatty liver disease / liver fat / commentary

References

[1] Bellentani S.The epidemiology of non-alcoholic fatty liver disease..Liver Int.2017;37 Suppl 1:81-4

[2] Younossi Z,Marietti M,Henry L.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention..Nat Rev Gastroenterol Hepatol2018;15:11-20

[3] Byrne CD.NAFLD: a multisystem disease..J Hepatol2015;62:S47-64

[4] Eslam M,George J.MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease..Gastroenterology2020;158:1999-2014.e1

[5] Eslam M,Sarin SK,Targher G.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement..J Hepatol2020;73:202-9

[6] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease..Mayo Clin Proc1980;55:434-8

[7] Schaffner F.Nonalcoholic fatty liver disease..Prog Liver Dis1986;8:283-98

[8] Neuschwander-Tetri BA.Nonalcoholic steatohepatitis: summary of an AASLD single topic conference..Hepatology2003;37:1202-19

[9] Loria P,Carulli N.Should nonalcoholic fatty liver disease be renamed?.Dig Dis2005;23:72-82

[10] Ratziu V,Cortez-Pinto H,Marchesini G.A position statement on NAFLD/NASH based on the EASL 2009 special conference..J Hepatol2010;53:372-84

[11] Brunt EM.Histopathology of non-alcoholic fatty liver disease..Clin Liver Dis2009;13:533-44

[12] Balmer ML.Non-alcoholic steatohepatitis - from NAFLD to MAFLD..Ther Umsch2011;68:183-8

[13] Bellentani S.Is it time to change NAFLD and NASH nomenclature?.Lancet Gastroenterol Hepatol2017;2:547-8

[14] Valenti L.Redefining fatty liver disease classification in 2020..Liver Int2020;40:1016-7

[15] Fouad Y,Bollipo S,Ajlouni Y.What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’..Liver Int2020;40:1254-61

[16] Tilg H.From NAFLD to MAFLD: when pathophysiology succeeds..Nat Rev Gastroenterol Hepatol2020;17:387-8

[17] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease..J Hepatol2016;64:1388-402

[18] Italian Association for the Study of the Liver (AISF)AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions..Dig Liver Dis2017;49:471-83

[19] Chalasani N,Lavine JE,Cusi K.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases..Hepatology2018;67:328-57

[20] Khoudari G,Noureddin M,Lopez R.Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort..World J Hepatol2019;11:710-8 PMCID:PMC6856017

[21] Åberg F,Puukka P,Jula A.Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population..Hepatology2018;67:2141-9

[22] Alberti KG,Grundy SM,Cleeman JI.Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity..Circulation2009;120:1640-5

[23] Bugianesi E,Vanni E,Marchesini G.Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?.Dig Liver Dis2004;36:165-73

[24] Marchesini G.Metabolic syndrome and NASH..Clin Liver Dis2007;11:105-17ix

[25] Anstee QM,Day CP.Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis..Nat Rev Gastroenterol Hepatol2013;10:330-44

[26] Lonardo A,Marchesini G,Loria P.Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome..Dig Liver Dis2015;47:181-90

[27] Lonardo A,Argo CK,Byrne CD.Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups..Dig Liver Dis2015;47:997-1006

[28] Tilg H,Roden M.NAFLD and diabetes mellitus..Nat Rev Gastroenterol Hepatol2017;14:32-42

[29] Byrne CD,Scorletti E.Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults..BMJ2018;362:k2734

[30] Gastaldelli A.From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options..JHEP Rep2019;1:312-28 PMCID:PMC7001557

[31] Khan RS,Cusi K.Modulation of insulin resistance in nonalcoholic fatty liver disease..Hepatology2019;70:711-24

[32] Lin S,Wang M,Liu Y.Comparison of MAFLD and NAFLD diagnostic criteria in real world..Liver Int2020;2082-9

[33] Targher G.Concordance of MAFLD and NAFLD diagnostic criteria in “real-world” data..Liver Int2020;

[34] Lu FB,Rios RS,Byrne CD.Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis..J Gastroenterol Hepatol2020;

[35] Younossi ZM,Sanyal A,Brunt E.From NAFLD to MAFLD: implications of a premature change in terminology..Hepatology2020;

[36] Yki-järvinen H.Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome..Lancet Diabetes Endocrinol2014;2:901-10

[37] Adams LA,Tilg H.Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases..Gut2017;66:1138-53

[38] Stefan N,Cusi K.Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies..Lancet Diabetes Endocrinol2019;7:313-24

[39] Targher G,Tilg H.NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications..Gut2020;69:1691-705

[40] Byrne CD.NAFLD as a driver of chronic kidney disease..J Hepatol2020;72:785-801

[41] Mantovani A,Mosca A,Byrne CD.Complications, morbidity and mortality of nonalcoholic fatty liver disease..Metabolism2020;154170

[42] Wieland AC,McDermott MT,Cicutto LC.Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk..J Clin Gastroenterol2015;49:e6-10

[43] Alemany-Pagès M,Araújo S,Ribeiro RT.Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance?.BMC Public Health2020;20:1142 PMCID:PMC7372774